
FDA clears Phase II study of VT-7208 in chronic spontaneous urticaria
The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase II study of Processa Pharmaceuticals’ VT-7208 in chronic spontaneous urticaria (CSU). Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase II proof-of-concept programmes, including… Read More

